Demographic and clinical characteristics
| . | Total population (N = 60) . | Eltrombopag switched (n = 38) . | Romiplostim switched (n = 22) . |
|---|---|---|---|
| Age, mean (SD), y | 58.0 (21.7) | 60.5 (21.2) | 53.7 (22.4) |
| Sex, n (%) | |||
| Female | 37 (61.7) | 22 (57.9) | 15 (68.2) |
| Male | 23 (38.3) | 16 (42.1) | 7 (31.8) |
| Race, n (%) | |||
| Asian | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Black or African American | 5 (8.3) | 3 (7.9) | 2 (9.1) |
| Native Hawaiian or other Pacific Islander | 1 (1.7) | 0 | 1 (4.5) |
| White | 43 (71.7) | 27 (71.1) | 16 (72.7) |
| Multiracial | 1 (1.7) | 0 | 1 (4.5) |
| Unknown | 3 (5.0) | 3 (7.9) | 0 |
| Not reported | 1 (1.7) | 1 (2.6) | 0 |
| Other | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 13 (21.7) | 10 (26.3) | 3 (13.6) |
| Not Hispanic or Latino | 46 (76.7) | 27 (71.1) | 19 (86.4) |
| Not reported | 1 (1.7) | 1 (2.6) | 0 |
| Baseline TSQM domain score, mean (SD) | |||
| Convenience | 71.8 (21.8) | 74.0 (19.4) | 67.9 (25.2) |
| Effectiveness | 66.7 (22.3) | 62.3 (23.3) | 74.0 (18.7) |
| Global satisfaction | 69.0 (18.8) | 66.4 (19.0) | 73.4 (18.1) |
| Side effects | 88.5 (24.1) | 86.7 (27.3) | 91.5 (17.8) |
| Baseline WHO Bleeding Scale,∗ n (%) | |||
| Grade 0 | 55 (91.7) | 34 (89.5) | 21 (95.5) |
| Grade 1 | 5 (8.3) | 4 (10.5) | 1 (4.5) |
| Baseline PC, mean (SD), ×109/L | 157.5 (118.2) | 137.7 (112.3) | 191.0 (122.9) |
| Time since ITP diagnosis (on the date of enrollment), median (min-max), y | 3.58 (0.2-31.0) | 3.63 (0.2-31.0) | 2.71 (0.4-21.3) |
| No. of platelet transfusions in the previous 1 y, mean (SD) | 0.85 (2.71) | 0.42 (0.95) | 1.59 (4.25) |
| No. of previous hospitalizations for ITP, mean (SD) | 1.55 (3.71) | 1.08 (1.55) | 2.36 (5.78) |
| No. of previous significant bleeding events | |||
| Mean (SD) | 0.55 (1.65) | 0.29 (0.61) | 1.00 (2.58) |
| No significant bleeds, n (%) | 44 (73.3) | 30 (78.9) | 14 (63.6) |
| 1 significant bleeding event, n (%) | 10 (16.7) | 5 (13.2) | 5 (22.7) |
| 2 significant bleeding events, n (%) | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| 3 significant bleeding events, n (%) | 1 (1.7) | 0 | 1 (4.5) |
| 12 significant bleeding events, n (%) | 1 (1.7) | 0 | 1 (4.5) |
| History of splenectomy | |||
| Yes | 8 (13.3) | 5 (13.2) | 3 (13.6) |
| No | 52 (86.7) | 33 (86.8) | 19 (86.4) |
| History of thromboembolic events | |||
| Yes | 13 (21.7) | 8 (21.1) | 5 (22.7) |
| No | 47 (78.3) | 30 (78.9) | 17 (77.3) |
| Duration of previous TPO-RA treatment, weeks | |||
| Mean (SD) | – | 74.3 (87.9) | 135.7 (136.6) |
| Most recent dose level,† n (%) | |||
| Low | – | 10 (26.3) | 14 (63.6) |
| Medium | – | 20 (52.6) | 4 (18.2) |
| High | – | 7 (18.4) | 1 (4.5) |
| Other | – | 1 (2.6) | 3 (13.6) |
| . | Total population (N = 60) . | Eltrombopag switched (n = 38) . | Romiplostim switched (n = 22) . |
|---|---|---|---|
| Age, mean (SD), y | 58.0 (21.7) | 60.5 (21.2) | 53.7 (22.4) |
| Sex, n (%) | |||
| Female | 37 (61.7) | 22 (57.9) | 15 (68.2) |
| Male | 23 (38.3) | 16 (42.1) | 7 (31.8) |
| Race, n (%) | |||
| Asian | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Black or African American | 5 (8.3) | 3 (7.9) | 2 (9.1) |
| Native Hawaiian or other Pacific Islander | 1 (1.7) | 0 | 1 (4.5) |
| White | 43 (71.7) | 27 (71.1) | 16 (72.7) |
| Multiracial | 1 (1.7) | 0 | 1 (4.5) |
| Unknown | 3 (5.0) | 3 (7.9) | 0 |
| Not reported | 1 (1.7) | 1 (2.6) | 0 |
| Other | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 13 (21.7) | 10 (26.3) | 3 (13.6) |
| Not Hispanic or Latino | 46 (76.7) | 27 (71.1) | 19 (86.4) |
| Not reported | 1 (1.7) | 1 (2.6) | 0 |
| Baseline TSQM domain score, mean (SD) | |||
| Convenience | 71.8 (21.8) | 74.0 (19.4) | 67.9 (25.2) |
| Effectiveness | 66.7 (22.3) | 62.3 (23.3) | 74.0 (18.7) |
| Global satisfaction | 69.0 (18.8) | 66.4 (19.0) | 73.4 (18.1) |
| Side effects | 88.5 (24.1) | 86.7 (27.3) | 91.5 (17.8) |
| Baseline WHO Bleeding Scale,∗ n (%) | |||
| Grade 0 | 55 (91.7) | 34 (89.5) | 21 (95.5) |
| Grade 1 | 5 (8.3) | 4 (10.5) | 1 (4.5) |
| Baseline PC, mean (SD), ×109/L | 157.5 (118.2) | 137.7 (112.3) | 191.0 (122.9) |
| Time since ITP diagnosis (on the date of enrollment), median (min-max), y | 3.58 (0.2-31.0) | 3.63 (0.2-31.0) | 2.71 (0.4-21.3) |
| No. of platelet transfusions in the previous 1 y, mean (SD) | 0.85 (2.71) | 0.42 (0.95) | 1.59 (4.25) |
| No. of previous hospitalizations for ITP, mean (SD) | 1.55 (3.71) | 1.08 (1.55) | 2.36 (5.78) |
| No. of previous significant bleeding events | |||
| Mean (SD) | 0.55 (1.65) | 0.29 (0.61) | 1.00 (2.58) |
| No significant bleeds, n (%) | 44 (73.3) | 30 (78.9) | 14 (63.6) |
| 1 significant bleeding event, n (%) | 10 (16.7) | 5 (13.2) | 5 (22.7) |
| 2 significant bleeding events, n (%) | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| 3 significant bleeding events, n (%) | 1 (1.7) | 0 | 1 (4.5) |
| 12 significant bleeding events, n (%) | 1 (1.7) | 0 | 1 (4.5) |
| History of splenectomy | |||
| Yes | 8 (13.3) | 5 (13.2) | 3 (13.6) |
| No | 52 (86.7) | 33 (86.8) | 19 (86.4) |
| History of thromboembolic events | |||
| Yes | 13 (21.7) | 8 (21.1) | 5 (22.7) |
| No | 47 (78.3) | 30 (78.9) | 17 (77.3) |
| Duration of previous TPO-RA treatment, weeks | |||
| Mean (SD) | – | 74.3 (87.9) | 135.7 (136.6) |
| Most recent dose level,† n (%) | |||
| Low | – | 10 (26.3) | 14 (63.6) |
| Medium | – | 20 (52.6) | 4 (18.2) |
| High | – | 7 (18.4) | 1 (4.5) |
| Other | – | 1 (2.6) | 3 (13.6) |